Alterity Therapeutics Limited (ATHE) has seen a push of 7.11% in premarket despite any latest news released by the company. However, the last trading session closed at $0.98 with an increase of 7.84%.
ATH434 Being Neuroprotective – Latest News by ATHE
On 28th January 2022, ATHE announced that the Journal of Parkinson’s Disease recently published evidence from an animal model of Multiple System Atrophy (MSA). MSA is a debilitating neurological disease for which there is no recognized treatment.
The preclinical findings are extremely important because they support the hypothesis. The hypothesis stated that by binding and redistributing excess iron in the brains of Parkinson’s disease patients, they can decrease synuclein aggregation and oxidative stress, as well as rescue neurotransmitters in multiple brain regions. This addresses the disease’s underlying pathology. Last but not the least, ATHE anticipates that these preclinical studies will lead to clinical benefit in MSA patients.
New US Patent – What’s up?
On 6th January 2022, ATHE reported that the company has been granted a new patent number by the USPTO. The USPTO prioritized the investigation of the composition of matter patent, “Compounds for and Methods of Treating Diseases.” The patent includes more than 80 new compounds and grants exclusivity to a new class of iron chaperones meant to disperse excess iron.
ATHE is still looking for new medication candidates to contribute to the portfolio and safeguard the neurodegenerative therapeutic approach. Moreover, ATHE is developing a strong basis as a leader in targeting iron for a possible disease-modifying therapy for critical neurological illnesses including Parkinson’s and Alzheimer’s.
First Regulatory Authorization by ATHE – What’s going on?
On 14th December 2021, ATHE announced that Alterity’s Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and very debilitating Parkinsonian illness, has been approved by the New Zealand Medicines and Medical Devices Safety Authority. The approval of the New Zealand health authorities to proceed with the Phase 2 clinical research is an important milestone. This happens because it opens the door for the study to begin in the first quarter of next year. By preventing -synuclein aggregation and restoring iron balance in the brain, ATH434 uses a novel strategy to treat the underlying pathophysiology of MSA.
